

DORC has obtained approval for sale of their EVA retina and cataract surgical system in the USA.

Launched in Europe in 2013, now in over 250 locations in Europe and with over 250,000 procedures performed. EVA is an integrated surgical system for retina, combined and cataract surgery. The launch of EVA in the USA is an important milestone forward in the investment of the company in American market and an indication of the commitment of DORC to providing an innovative, economically competitive alternative in the market.



"We are very proud to announce the launch of EVA in the USA" commented Ilze Timmers, CEO DORC International. "This significant milestone follows closely on the heels of the EVA approval in Japan, last month. We now have our flagship next generation Vit-Phaco machine available for sale in 3 of the 5 biggest economies in the world. Moreover, it is an exciting day for EVA, a system optimized for ophthalmic surgery, based on design input from ophthalmic surgeons around the world."

Gaurav K Shah MD, Co-Director of Retina Fellowship, The Retina Institute, Prof of Clinical Ophthalmology – Washington University. "We are very excited to see that this day has finally

arrived. The EVA machine will allow both vacuum and flow options in a seamless fashion for the OR of the 21st century. American Surgeons now have the option of the most technically advanced vitrectomy machine that our European counterparts have had for over a year now. This is the result of the R&D Innovation that is endemic in the DORC culture and will augment the Strong history of 1 st's in their 30 year history."

EVA includes a number of innovative technologies designed to provide the surgeon with enhanced control and flexibility in surgery – including the unique VTI pump system (offering both flow and vacuum fluidics), TDC (two dimensional cutting) vitrectome with cuts speeds of up to 16,000 CPM, LED illumination and AIC – active infusion compensation.